Coyne DW - Search Results

1

Managing anemia in for-profit dialysis chains: when ethics and business conflict.

Coyne DW. Coyne DW. Semin Dial. 2009 Jan-Feb;22(1):18-21. doi: 10.1111/j.1525-139X.2008.00531.x. Semin Dial. 2009. PMID: 19250444 Review.

2

Increased plasma leptin concentration in end-stage renal disease.

Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M. Merabet E, et al. Among authors: coyne dw. J Clin Endocrinol Metab. 1997 Mar;82(3):847-50. doi: 10.1210/jcem.82.3.3817. J Clin Endocrinol Metab. 1997. PMID: 9062494

3

Impaired delivery of hemodialysis prescriptions: an analysis of causes and an approach to evaluation.

Coyne DW, Delmez J, Spence G, Windus DW. Coyne DW, et al. J Am Soc Nephrol. 1997 Aug;8(8):1315-8. J Am Soc Nephrol. 1997. PMID: 9259360

4

Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis.

Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne DW. Dagogo-Jack S, et al. Among authors: coyne dw. Perit Dial Int. 1998 Jan-Feb;18(1):34-40. Perit Dial Int. 1998. PMID: 9527027

5

Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation.

Landt M, Brennan DC, Parvin CA, Flavin KS, Dagogo-Jack S, Coyne DW. Landt M, et al. Among authors: coyne dw. Nephrol Dial Transplant. 1998 Sep;13(9):2271-5. doi: 10.1093/ndt/13.9.2271. Nephrol Dial Transplant. 1998. PMID: 9761508

6

High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients.

Coyne DW, Dagogo-Jack S, Klein S, Merabet E, Audrain J, Landt M. Coyne DW, et al. Am J Kidney Dis. 1998 Dec;32(6):1031-5. doi: 10.1016/s0272-6386(98)70079-4. Am J Kidney Dis. 1998. PMID: 9856520

7

Leptin elimination in hyperleptinaemic peritoneal dialysis patients.

Landt M, Parvin CA, Dagogo-Jack S, Bryant B, Coyne DW. Landt M, et al. Among authors: coyne dw. Nephrol Dial Transplant. 1999 Mar;14(3):732-7. doi: 10.1093/ndt/14.3.732. Nephrol Dial Transplant. 1999. PMID: 10193829

8

Network 12 hepatitis B vaccination quality improvement program: an educational program directed at physicians, staff, and patients.

Coyne DW, Taylor LF, Yelton S, Long C, Preston SD. Coyne DW, et al. Adv Ren Replace Ther. 2000 Oct;7(4 Suppl 1):S71-5. Adv Ren Replace Ther. 2000. PMID: 11053590

9

Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.

Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG; Ferlecit Investigators. Coyne DW, et al. Kidney Int. 2003 Jan;63(1):217-24. doi: 10.1046/j.1523-1755.2003.00703.x. Kidney Int. 2003. PMID: 12472786 Clinical Trial.

10

Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Staniforth ME, Cheng SC, Coyne DW. Staniforth ME, et al. Among authors: coyne dw. Clin Nephrol. 2005 Jun;63(6):454-60. doi: 10.5414/cnp63454. Clin Nephrol. 2005. PMID: 15960147

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results